Most people with hypertension and CKD, especially those with a urine albumin:creatinine ratio ≥3 mg/mmol, should be treated with a renin-angiotensin system inhibitor to which, in selected individuals, a sodium-glucose co-transporter inhibitors type 2 and non-steroidal mineralocorticoid receptor antagonist may be added, followed by additional antihypertensives to achieve goal BP. This evidence concerns the gene NR3C2 and hypertensive disorder.